Regenicin, Inc. (RGIN)

0.0001 0.0000 (0.00%) 收市：02:19PM EDT

Regenicin, Inc.

10 High Court
Little Falls, NJ 07424
United States
973 557 8914
https://www.regenicin.com

版塊: Healthcare
行業: Biotechnology
全職員工: 3

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Randall E. McCoy	Chairman, CEO & President	250k	無	1949
Mr. John J. Weber	CFO & Director	125k	無	1950
Dr. J. Roy Nelson Ph.D.	Controller & Chief Science Officer	150k	無	1948

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

公司管治

截至 無 止，Regenicin, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。